- First quarter 2023 sales of $2.3 billion, up 7%, or 11%
constant currency(1) (cc)
- First quarter 2023 diluted EPS of $0.35, up 3%, or up 26%
cc; core diluted EPS(2) of $0.70 up 3%, or 14% cc
- Dividend of CHF 0.21 per share approved by shareholders at
the Annual General Meeting on May 5, 2023
- Raised full year 2023 cc sales and core diluted EPS growth
outlook
Ad Hoc Announcement Pursuant to Art. 53 LR
Regulatory News:
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported
its financial results for the three months ended March 31, 2023.
For the first quarter of 2023, sales were $2.3 billion, an increase
of 7% on a reported basis and 11% on a constant currency basis(1),
as compared to the same quarter of the previous year. Alcon
reported diluted earnings per share of $0.35 and core diluted
earnings per share(2) of $0.70 in the first quarter of 2023.
David J. Endicott, Alcon's Chief Executive Officer, said,
"Thanks to the hard work and dedication of our more than 25,000
associates, 2023 is off to a strong start. These outstanding
results are a testament to the durability of the eye care markets,
competitive strength of our business and expertise of our
team."
Mr. Endicott continued, "As we look to the remainder of the
year, we will continue to focus our efforts on value creation
through accelerating innovation and driving above-market sales
growth."
First quarter 2023 key figures
Three months ended March
31
2023
2022
Net sales ($ millions)
2,333
2,175
Operating margin (%)
11.5%
11.3%
Core operating margin (%)(2)
20.6%
20.6%
Diluted earnings per share ($)
0.35
0.34
Core diluted earnings per share ($)(2)
0.70
0.68
(1)
Constant currency is a non-IFRS
measure. Refer to the 'Footnotes' section for additional
information.
(2)
Core results, such as core
operating margin and core diluted EPS, are non-IFRS measures. Refer
to the 'Footnotes' section for additional information.
First quarter 2023 results
Sales for the first quarter of 2023 were $2.3 billion, an
increase of 7% on a reported basis and 11% on a constant currency
basis, compared to the first quarter of 2022.
The following table highlights net sales by segment for the
first quarter of 2023:
Three months ended March
31
Change %
($ millions unless indicated
otherwise)
2023
2022
$
cc(1)
Surgical
Implantables
427
455
(6
)
(3
)
Consumables
656
601
9
13
Equipment/other
221
203
9
14
Total Surgical
1,304
1,259
4
8
Vision Care
Contact lenses
615
557
10
14
Ocular health
414
359
15
19
Total Vision Care
1,029
916
12
16
Net sales to third parties
2,333
2,175
7
11
Surgical growth driven by strong consumables and equipment
sales, partially offset by PCIOLs in South Korea
For the first quarter of 2023, Surgical net sales, which include
implantables, consumables and equipment/other, were $1.3 billion,
an increase of 4% on a reported basis and 8% on a constant currency
basis versus the first quarter of 2022.
- Implantables net sales were $427 million, a decrease of 6%.
Presbyopia correcting intraocular lens (PCIOLs) sales in South
Korea decreased approximately $47 million due to an insurance
reimbursement change that took effect April 1, 2022. This decline
was partially offset by an increase in intraocular lens sales
across other geographies. There were unfavorable currency impacts
of 3%. Implantables net sales decreased 3% constant currency.
- Consumables net sales were $656 million, an increase of 9%,
reflecting favorable market conditions across geographies and price
increases, partially offset by unfavorable currency impacts of 4%.
Consumables net sales increased 13% constant currency.
- Equipment/other net sales were $221 million, an increase of 9%,
reflecting continued strong demand in international markets for
cataract and vitreoretinal equipment, partially offset by
unfavorable currency impacts of 5%. Equipment/other net sales
increased 14% constant currency.
Double-digit Vision Care growth reflects strength in contact
lenses and eye drops, including acquired products
For the first quarter of 2023, Vision Care net sales, which
include contact lenses and ocular health, were $1.0 billion, an
increase of 12% on a reported basis and 16% on a constant currency
basis, versus the first quarter of 2022. Reported sales growth
includes approximately 5 percentage points of contribution from
products acquired in 2022.
- Contact lenses net sales of $615 million, an increase of 10%,
reflected continued growth in silicone hydrogel contact lenses,
including the Precision1 and Total product families, and price
increases. Growth was partially offset by unfavorable currency
impacts of 4%. Contact lenses net sales increased 14% constant
currency.
- Ocular health net sales were $414 million, an increase of 15%,
primarily driven by the portfolio of eye drops, including acquired
ophthalmic pharmaceutical products, and price increases. This
growth was partially offset by unfavorable currency impacts of 4%.
Ocular health net sales increased 19% in constant currencies.
Operating income
First quarter 2023 operating income was $268 million and
operating margin was 11.5%. Operating margin increased 0.2
percentage points, reflecting improved underlying operating
leverage from higher sales and manufacturing efficiencies. This was
partially offset by unfavorable product mix from lower PCIOL sales
in South Korea, higher amortization for intangible assets due to
recent acquisitions, higher research and development (R&D)
investment following the acquisition of Aerie and a negative 1.5
percentage point impact from currency. Operating margin increased
1.7 percentage points on a constant currency basis.
Adjustments to arrive at core operating income(2) in the current
year period were $212 million, mainly due to $173 million of
amortization. Excluding these and other adjustments, first quarter
of 2023 core operating income was $480 million.
First quarter 2023 core operating margin of 20.6% was in-line
with the prior year period, reflecting improved underlying
operating leverage from higher sales and manufacturing
efficiencies. This was offset by unfavorable product mix from lower
PCIOL sales in South Korea, higher R&D investment following the
acquisition of Aerie and a negative 1.3 percentage point impact
from currency. Core operating margin increased 1.3 percentage
points on a constant currency basis.
Diluted earnings per share (EPS)
First quarter 2023 earnings per share of $0.35 increased 3%, or
26% on a constant currency basis. Core diluted earnings per share
of $0.70 increased 3%, or 14% on a constant currency basis.
Dividend
On May 5, 2023, at the Company's Annual General Meeting, the
shareholders approved a dividend of CHF 0.21 per share, which will
be paid on or around May 12, 2023. The total dividend payments will
amount to a maximum of $118 million, using the CHF/USD exchange
rate as of May 5, 2023.
Balance sheet and cash flow highlights
The Company ended the first quarter with a cash position of $889
million. Cash flows from operations for the first quarter of 2023
totaled $85 million, compared to $66 million in the prior year. The
current year includes increased collections associated with higher
sales, partially offset by the negative impact of foreign currency
rates on operating results, increased cash outflows from higher
transformation payments, other operating expenditures, including
increased R&D, and increased taxes paid due to the timing of
tax payments. Both periods were impacted by semi-annual interest
payments and changes in net working capital.
Free cash flow(3) was an outflow of $19 million in the first
quarter of 2023, compared to an outflow of $52 million in the
previous year. The change in free cash flow was primarily driven by
increased cash flows from operations and decreased purchases of
property, plant and equipment. Free cash flow was an outflow for
both periods due to the timing of annual associate short-term
incentive payments.
(3)
Free cash flow is a non-IFRS
measure. Refer to the 'Footnotes' section for additional
information.
2023 outlook
The Company updated its 2023 outlook as per the table below.
2023 outlook(4)
as of February
as of May
Commentary
Net sales (USD)
$9.2 to $9.4 billion
$9.2 to $9.4 billion
Maintain
Change vs. prior year (cc)(1)
+6% to +8%
+7% to +9%
Increase
Core operating margin(2)
19.5% to 20.5%
19.5% to 20.5%
Maintain
Interest expense and Other
financial income & expense
$260 to $280 million
$245 to $255 million
Decrease
Core effective tax rate(5)
17% to 19%
17% to 19%
Maintain
Core diluted EPS(2)
$2.55 to $2.65
$2.55 to $2.65
Trending toward high end of
range
Change vs. prior year (cc)(1)
+16% to +20%
+20% to +24%
Increase
This outlook assumes the following:
- Markets grow at or slightly below historical averages in the
second half of the year;
- Exchange rates as of mid-April prevail through year-end;
- Inflation and supply chain challenges continue through
2023;
- Approximately 497 million weighted-averaged diluted
shares.
(4)
The forward-looking guidance
included in this press release cannot be reconciled to the
comparable IFRS measures without unreasonable effort, because we
are not able to predict with reasonable certainty the ultimate
amount or nature of exceptional items in the fiscal year. Refer to
the 'Footnotes' section for additional information.
(5)
Core effective tax rate, a
non-IFRS measure, is the applicable annual tax rate on core taxable
income. Refer to the 'Footnotes' section for additional
information.
Webcast and Conference Call Instructions
The Company will host a conference call on May 10, 2023 at 2:00
p.m. Central European Time / 8:00 a.m. Eastern Time to discuss its
first quarter 2023 earnings results. The webcast can be accessed
online through Alcon's Investor Relations website,
investor.alcon.com. Listeners should log on approximately 10
minutes in advance. A replay will be available online within 24
hours after the event.
The Company's interim financial report and supplemental
presentation materials can be found online through Alcon's Investor
Relations website, or by clicking on the link:
https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2023/Alcons-First-Quarter-2023-Earnings-Conference-Call/default.aspx
Footnotes (pages 1-4)
(1)
Constant currency (cc) is a
non-IFRS measure. Growth in constant currency (cc) is calculated by
translating the current year’s foreign currency items into US
dollars using average exchange rates from the historical
comparative period and comparing them to the values from the
historical comparative period in US dollars. An explanation of
non-IFRS measures can be found in the 'Non-IFRS measures as defined
by the Company' section.
(2)
Core results, such as core
operating margin and core EPS, are non-IFRS measures. For
additional information, including a reconciliation of such core
results to the most directly comparable measures presented in
accordance with IFRS, see the explanation of non-IFRS measures and
reconciliation tables in the 'Non-IFRS measures as defined by the
Company' and 'Financial tables' sections.
(3)
Free cash flow is a non-IFRS
measure. For additional information regarding free cash flow, see
the explanation of non-IFRS measures and reconciliation tables in
the 'Non-IFRS measures as defined by the Company' and 'Financial
tables' sections.
(4)
The forward-looking guidance
included in this press release cannot be reconciled to the
comparable IFRS measures without unreasonable efforts, because we
are not able to predict with reasonable certainty the ultimate
amount or nature of exceptional items in the fiscal year. Refer to
the section 'Non-IFRS measures as defined by the Company' for more
information.
(5)
Core effective tax rate, a
non-IFRS measure, is the applicable annual tax rate on core taxable
income. For additional information, see the explanation regarding
reconciliation of forward-looking guidance in the 'Non-IFRS
measures as defined by the Company' section.
Cautionary Note Regarding Forward-Looking Statements
This press release contains, and our officers and
representatives may from time to time make, certain
“forward-looking statements” within the meaning of the safe harbor
provisions of the US Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
“anticipate,” “intend,” “commitment,” “look forward,” “maintain,”
“plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods. Examples
of forward-looking statements include, among others, statements we
make regarding our liquidity, revenue, gross margin, operating
margin, effective tax rate, foreign currency exchange movements,
earnings per share, our plans and decisions relating to various
capital expenditures, capital allocation priorities and other
discretionary items such as our transformation program, market
growth assumptions, our sustainability and diversity plans,
targets, goals and expectations, and generally, our expectations
concerning our future performance.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict such as:
- cybersecurity breaches or other disruptions of our information
technology systems;
- compliance with data privacy, identity protection and
information security laws;
- our ability to comply with the US Foreign Corrupt Practices Act
of 1977 and other applicable anti-corruption laws, particularly
given that we have entered into a three-year Deferred Prosecution
Agreement with the US Department of Justice;
- the impact of a disruption in our global supply chain or
important facilities;
- supply constraints and increases in the cost of energy;
- our ability to forecast sales demand and manage our inventory
levels and the changing buying patterns of our customers;
- our ability to manage environmental, social and governance
matters to the satisfaction of our many stakeholders, some of which
may have competing interests;
- our success in completing and integrating strategic
acquisitions;
- the success of our research and development efforts, including
our ability to innovate to compete effectively;
- global and regional economic, financial, legal, tax, political
and social change;
- our ability to comply with all laws to which we may be
subject;
- pricing pressure from changes in third party payor coverage and
reimbursement methodologies;
- our ability to properly educate and train healthcare providers
on our products;
- our reliance on outsourcing key business functions;
- our ability to attract and retain qualified personnel;
- the impact of unauthorized importation of our products from
countries with lower prices to countries with higher prices;
- the ability to obtain regulatory clearance and approval of our
products as well as compliance with any post-approval obligations,
including quality control of our manufacturing;
- our ability to protect our intellectual property;
- our ability to service our debt obligations;
- the need for additional financing through the issuance of debt
or equity;
- the effects of litigation, including product liability lawsuits
and governmental investigations;
- effect of product recalls or voluntary market withdrawals;
- the accuracy of our accounting estimates and assumptions,
including pension and other post-employment benefit plan
obligations and the carrying value of intangible assets;
- legislative, tax and regulatory reform;
- the impact of being listed on two stock exchanges;
- the ability to declare and pay dividends;
- the different rights afforded to our shareholders as a Swiss
corporation compared to a US corporation; and
- the effect of maintaining or losing our foreign private issuer
status under U.S. securities laws.
Additional factors are discussed in our filings with the United
States Securities and Exchange Commission, including our Form 20-F.
Should one or more of these uncertainties or risks materialize, or
should underlying assumptions prove incorrect, actual results may
vary materially from those anticipated. Therefore, you should not
rely on any of these forward-looking statements. Forward-looking
statements in this press release speak only as of the date of its
filing, and we assume no obligation to update forward-looking
statements as a result of new information, future events or
otherwise.
Intellectual Property
This report may contain references to our proprietary
intellectual property. All product names appearing in italics or
ALL CAPS are trademarks owned by or licensed to Alcon Inc. Product
names identified by a "®" or a "™" are trademarks that are not
owned by or licensed to Alcon or its subsidiaries and are the
property of their respective owners.
Non-IFRS measures as defined by the Company
Alcon uses certain non-IFRS metrics when measuring performance,
including when measuring current period results against prior
periods, including core results, percentage changes measured in
constant currencies, free cash flow, and net (debt)/liquidity.
Because of their non-standardized definitions, the non-IFRS
measures (unlike IFRS measures) may not be comparable to the
calculation of similar measures of other companies. These
supplemental non-IFRS measures are presented solely to permit
investors to more fully understand how Alcon management assesses
underlying performance. These supplemental non-IFRS measures are
not, and should not be viewed as, a substitute for IFRS
measures.
Core results
Alcon core results, including core operating income and core net
income, exclude all amortization and impairment charges of
intangible assets, excluding software, net gains and losses on fund
investments and equity securities valued at fair value through
profit and loss ("FVPL"), fair value adjustments of financial
assets in the form of options to acquire a company carried at FVPL,
obligations related to product recalls, and certain acquisition
related items. The following items that exceed a threshold of $10
million and are deemed exceptional are also excluded from core
results: integration and divestment related income and expenses,
divestment gains and losses, restructuring charges/releases and
related items, legal related items, gains/losses on early
extinguishment of debt or debt modifications, past service costs
for post-employment benefit plans, impairments of property, plant
and equipment and software, as well as income and expense items
that management deems exceptional and that are or are expected to
accumulate within the year to be over a $10 million threshold.
Taxes on the adjustments between IFRS and core results take into
account, for each individual item included in the adjustment, the
tax rate that will finally be applicable to the item based on the
jurisdiction where the adjustment will finally have a tax impact.
Generally, this results in amortization and impairment of
intangible assets and acquisition-related restructuring and
integration items having a full tax impact. There is usually a tax
impact on other items, although this is not always the case for
items arising from legal settlements in certain jurisdictions.
Alcon believes that investor understanding of its performance is
enhanced by disclosing core measures of performance because, since
they exclude items that can vary significantly from period to
period, the core measures enable a helpful comparison of business
performance across periods. For this same reason, Alcon uses these
core measures in addition to IFRS and other measures as important
factors in assessing its performance.
A limitation of the core measures is that they provide a view of
Alcon operations without including all events during a period, such
as the effects of an acquisition, divestment, or
amortization/impairments of purchased intangible assets and
restructurings.
Constant currencies
Changes in the relative values of non-US currencies to the US
dollar can affect Alcon's financial results and financial position.
To provide additional information that may be useful to investors,
including changes in sales volume, we present information about
changes in our net sales and various values relating to operating
and net income that are adjusted for such foreign currency
effects.
Constant currency calculations have the goal of eliminating two
exchange rate effects so that an estimate can be made of underlying
changes in the Consolidated Income Statement excluding:
- the impact of translating the income statements of consolidated
entities from their non-US dollar functional currencies to the US
dollar; and
- the impact of exchange rate movements on the major transactions
of consolidated entities performed in currencies other than their
functional currency.
Alcon calculates constant currency measures by translating the
current year's foreign currency values for sales and other income
statement items into US dollars, using the average exchange rates
from the historical comparative period and comparing them to the
values from the historical comparative period in US dollars.
Free cash flow
Alcon defines free cash flow as net cash flows from operating
activities less cash flow associated with the purchase or sale of
property, plant and equipment. Free cash flow is presented as
additional information because Alcon management believes it is a
useful supplemental indicator of Alcon's ability to operate without
reliance on additional borrowing or use of existing cash. Free cash
flow is not intended to be a substitute measure for net cash flows
from operating activities as determined under IFRS.
Net (debt)/liquidity
Alcon defines net (debt)/liquidity as current and non-current
financial debt less cash and cash equivalents, current investments
and derivative financial instruments. Net (debt)/liquidity is
presented as additional information because management believes it
is a useful supplemental indicator of Alcon's ability to pay
dividends, to meet financial commitments and to invest in new
strategic opportunities, including strengthening its balance
sheet.
Growth rate and margin
calculations
For ease of understanding, Alcon uses a sign convention for its
growth rates such that a reduction in operating expenses or losses
compared to the prior year is shown as a positive growth.
Gross margins, operating income/(loss) margins and core
operating income margins are calculated based upon net sales to
third parties unless otherwise noted.
Reconciliation of guidance for
forward-looking non-IFRS measures
The forward-looking guidance included in this press release
cannot be reconciled to the comparable IFRS measures without
unreasonable efforts, because we are not able to predict with
reasonable certainty the ultimate amount or nature of exceptional
items in the fiscal year. These items are uncertain, depend on many
factors and could have a material impact on our IFRS results for
the guidance period.
Financial tables
Net sales by region
Three months ended March
31
($ millions unless indicated
otherwise)
2023
2022
United States
1,078
46%
939
43%
International
1,255
54%
1,236
57%
Net sales to third parties
2,333
100%
2,175
100%
Consolidated Income Statement (unaudited)
Three months ended March
31
($ millions except earnings per share)
2023
2022
Net sales to third parties
2,333
2,175
Other revenues
19
14
Net sales and other revenues
2,352
2,189
Cost of net sales
(1,030
)
(967
)
Cost of other revenues
(17
)
(14
)
Gross profit
1,305
1,208
Selling, general & administration
(785
)
(741
)
Research & development
(202
)
(166
)
Other income
5
9
Other expense
(55
)
(64
)
Operating income
268
246
Interest expense
(47
)
(29
)
Other financial income & expense
(8
)
(17
)
Income before taxes
213
200
Taxes
(39
)
(32
)
Net income
174
168
Earnings per share ($)
Basic
0.35
0.34
Diluted
0.35
0.34
Weighted average number of shares
outstanding (millions)
Basic
492.4
490.9
Diluted
495.5
494.0
Balance sheet highlights
($ millions)
March 31, 2023
December 31, 2022
Cash and cash equivalents
889
980
Current financial debts
102
107
Non-current financial debts
4,584
4,541
Free cash flow
The following is a summary of free cash flow for the three
months ended March 31, 2023 and 2022, together with a
reconciliation to net cash flows from operating activities, the
most directly comparable IFRS measure:
Three months ended March
31
($ millions)
2023
2022
Net cash flows from operating
activities
85
66
Purchase of property, plant &
equipment
(104
)
(118
)
Free cash flow
(19
)
(52
)
Net (debt)/liquidity
($ millions)
At March 31, 2023
Current financial debt
(102
)
Non-current financial debt
(4,584
)
Total financial debt
(4,686
)
Less liquidity:
Cash and cash equivalents
889
Derivative financial instruments
5
Total liquidity
894
Net (debt)
(3,792
)
Reconciliation of IFRS results to core results
Three months ended March 31, 2023
($ millions except earnings per share)
IFRS results
Amortization of certain
intangible assets(1)
Transformation
costs(2)
Other items(4)
Core results
Gross profit
1,305
169
—
4
1,478
Operating income
268
173
26
13
480
Income before taxes
213
173
26
13
425
Taxes(5)
(39
)
(31
)
(5
)
(3
)
(78
)
Net income
174
142
21
10
347
Basic earnings per share ($)
0.35
0.70
Diluted earnings per share ($)
0.35
0.70
Basic - weighted average shares
outstanding (millions)(6)
492.4
492.4
Diluted - weighted average shares
outstanding (millions)(6)
495.5
495.5
Refer to the associated explanatory footnotes at the end of the
'Reconciliation of IFRS results to core results' tables.
Three months ended March 31, 2022
($ millions except earnings per share)
IFRS results
Amortization of certain
intangible assets(1)
Transformation
costs(2)
Legal items(3)
Other items(4)
Core results
Gross profit
1,208
140
—
—
9
1,357
Operating income
246
146
15
20
21
448
Income before taxes
200
146
15
20
21
402
Taxes(5)
(32
)
(25
)
(2
)
(5
)
—
(64
)
Net income
168
121
13
15
21
338
Basic earnings per share ($)
0.34
0.69
Diluted earnings per share ($)
0.34
0.68
Basic - weighted average shares
outstanding (millions)(6)
490.9
490.9
Diluted - weighted average shares
outstanding (millions)(6)
494.0
494.0
Refer to the associated explanatory footnotes at the end of the
'Reconciliation of IFRS results to core results' tables.
Explanatory footnotes to IFRS to core reconciliation
tables
(1)
Includes recurring amortization
for all intangible assets other than software.
(2)
Transformation costs, primarily
related to restructuring and third party consulting fees, for the
multi-year transformation program.
(3)
Includes a provision for a legal
settlement.
(4)
For the three months ended March
31, 2023, Gross profit includes the amortization of inventory fair
value adjustments related to a recent acquisition. Operating income
also includes integration related expenses for a recent acquisition
and fair value adjustments of financial assets.
For the three months ended March
31, 2022, Gross profit includes charges related to the conflict in
Ukraine and amortization of inventory fair value adjustments
related to an acquisition. Operating income also includes charges
related to the conflict in Ukraine, integration related expenses
and fair value adjustments of financial assets.
(5)
For the three months ended March
31, 2023, tax associated with operating income core adjustments of
$212 million totaled $39 million with an average tax rate of
18.4%.
For the three months ended March
31, 2022, total tax adjustments of $32 million include tax
associated with operating income core adjustments, partially offset
by discrete tax items. Tax associated with operating income core
adjustments of $202 million totaled $35 million with an average tax
rate of 17.3%.
(6)
Core basic earnings per share is
calculated using the weighted-average shares of common stock
outstanding during the period. Core diluted earnings per share also
contemplate dilutive shares associated with unvested equity-based
awards as described in Note 4 to the Condensed Consolidated Interim
Financial Statements.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of people in
over 140 countries each year living with conditions like cataracts,
glaucoma, retinal diseases and refractive errors. Our more than
25,000 associates are enhancing the quality of life through
innovative products, partnerships with Eye Care Professionals and
programs that advance access to quality eye care. Learn more at
www.alcon.com.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230507005025/en/
Investor Relations Daniel
Cravens Allen Trang + 41 589 112 110 (Geneva) + 1 817 615 2789
(Fort Worth) investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
過去 株価チャート
から 4 2024 まで 5 2024
Alcon (NYSE:ALC)
過去 株価チャート
から 5 2023 まで 5 2024